Publications

The Internet of Things – IoT

The Internet of Things: The saviour of healthcare, or disaster waiting to happen? Business Insider defines the Internet of Things (“IoT”) as ‘a network of internet-connected objects able to collect and exchange data using embedded sensors’. Healthcare is a key area in which the IoT is set to revolutionise the way we live. The so-called Internet… Read more »

Protection for cannabis-based IP

Protection for cannabis-based IP in the wake of announcement of impending legalisation of medicinal cannabis   The legalisation of medicinal and recreational cannabis in several US states, Canada and some European countries has resulted in a new economic market rising from what was previously an illegal trade. Meanwhile, in the UK, the recent cases of… Read more »

J. Choo Limited v Liangliang Ren

“If your hair is done properly and you’re wearing good shoes, you can get away with anything.” – Iris Apfel   Introduction Not according to the EUIPO in the recent decision in Opposition No. B002757717 of J. Choo Limited v Liangliang Ren, when the Opposition Division handed down a decision to reject the mark:  … Read more »

EU: Falsified Medicines Directive: Implications for parallel importers and of Brexit

EU: Falsified Medicines Directive: Implications for parallel importers and of Brexit This article was updated: 8 October 2018   Introduction to the Falsified Medicines Directive Directive 2011/62/EU, better known as “The Falsified Medicines Directive” or “FMD”, came into force on 2 January 2013, with the aim of preventing falsified medicines from entering the legitimate supply… Read more »

WIPO Magazine has announced the launch of a new tool linking patents and drugs: Pat-INFORMED

WIPO Magazine has announced[1] the launch of a new tool linking patents and drugs: Pat-INFORMED The concept The World Intellectual Property Organization (WIPO) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), together with 20 participating global pharmaceutical companies, have joined forces to globalise the concept of the US’s ‘Orange Book’. Most drugs have… Read more »

“It’s immoral!” Pitfalls of failing to register your trademarks; increased risks in China.

“It’s immoral!” Pitfalls of failing to register your trademarks; increased risks in China. Background: For a number of reasons, it is generally recognised as best practice is to secure a trade mark registration for your brands. Despite your best endeavours, however, trade mark applications can be rejected on a range of different grounds, including “absolute”… Read more »

Brexit: Considerations for European Union Trade Marks and Registered Community Designs

Brexit: Considerations for European Union Trade Marks and Registered Community Designs What is the current situation? The UK is to leave the EU (“Brexit”) on 29 March 2019.  When Brexit becomes fully effective, EU unitary trade mark registrations (“EUTMs”) and registered Community designs (“RCDs”) will cease to have effect in the UK, but will continue… Read more »

Preparations for AI patenting in Europe

Preparations for AI patenting in Europe Patent Partner, Mike Jennings recently wrote a short article on Artificial Intelligence Patenting in Europe for Bio Science today magazine which discusses briefly the timelines of the patenting process and how current legislation has and will continue to change to keep up with the fast technological developments in the industry…. Read more »

UK and the UPC: What Will Happen Post-Brexit?

UK and the UPC:What Will Happen Post-Brexit? Partner and Solicitor Geoff Hussey, and  Patent Attorney Nick South write for Lawyer Monthly on behalf of the Charted Institute of Patent Attorneys on Brexit, and what is likely to happen over the next 9 months.    This article was published originally by Lawyer Monthly  on 29 June… Read more »

Assessment of “plausibility” requirement from the EPO perspective

Assessment of “plausibility” requirement from the EPO perspective Introduction This article considers how the EPO views the requirement of “plausibility”, which can arise during both the assessment of “sufficient disclosure” of the invention and “inventive step” in proceedings before the EPO, particularly in relation to inventions in the Pharmaceuticals and Life Sciences field. The EPO… Read more »

Categories

Archives